RO-0282425

RO-0282425
Clinical data
Other namesRO0282425
Routes of
administration		Unspecified[1]
Drug classMelanocortin MC4 receptor agonist
ATC code
  • None

RO-0282425 is a melanocortin MC4 receptor agonist which was under development for the treatment of erectile dysfunction but was never marketed.[1][2] Its route of administration was unspecified.[1] The drug was under development by Roche.[1][2] It reached phase 2 clinical trials by 2005 but its development was subsequently discontinued.[1][2] The chemical structure of RO-0282425, and whether it is a small molecule or a peptide, do not appear to have been disclosed.[1]

See also

References

  1. ^ a b c d e f "RO 0282425". AdisInsight. 4 March 2010. Retrieved 27 January 2026.
  2. ^ a b c "Delving into the Latest Updates on RO-0282425 with Synapse". Synapse. 3 January 2026. Retrieved 27 January 2026.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.